Collaborating for Future Progress
Conversations: Collaborating for Future Progress
02.26.14 | By
The existing model of bringing new medicines to patients is a costly, exhaustive, and thorough process. In fact, to develop a new medicine under the federal process takes about $1 billion and 10 years — with a failure rate of roughly 99 percent. That’s why PhRMA, 10 major biopharmaceutical companies, several non-profit organizations, and the National Institutes of Health are joining forces to form the Accelerating Medicines Partnership (AMP).
AMP’s goal is to transform the development of new diagnostics and treatments by jointly identifying and validating promising biological targets of disease, increase efficiency, improve the clinical trial process, and increase the number of and effectiveness of new targeted therapies. Data and analysis from the $230 million partnership, managed by the Foundation for the NIH, will further be publically accessible to the biological community and hopefully lead to new treatment options.
AMP will begin with three to five-year pilot projects focused on disease areas: Alzheimer’s, type 2 diabetes and autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus (lupus).
PhRMA is extremely excited about this new partnership, which is why we posed the following question for our Conversations forum:
Earlier this month, the National Institutes of Health, 10 biopharmaceutical companies, PhRMA and several non-profit disease foundations joined forces to transform the current model for developing new medicines and diagnostics. What are some realistic expectations that can come from the Accelerating Medicines Partnership?
We look forward to learning what contributors think about AMP, and encourage you to join the conversation by sharing your thoughts in the comment section.